Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Non-Current Assets (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Non-Current Assets data on record, last reported at $4.6 million in Q4 2025.

  • For Q4 2025, Non-Current Assets rose 55.4% year-over-year to $4.6 million; the TTM value through Dec 2025 reached $14.2 million, down 17.76%, while the annual FY2025 figure was $4.6 million, 55.4% up from the prior year.
  • Non-Current Assets reached $4.6 million in Q4 2025 per VRCA's latest filing, down from $4.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $6.1 million in Q2 2022 and bottomed at $2.3 million in Q2 2025.
  • Average Non-Current Assets over 5 years is $4.9 million, with a median of $5.4 million recorded in 2023.
  • The widest YoY moves for Non-Current Assets: up 55.4% in 2025, down 50.43% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $5.8 million in 2021, then dropped by 3.29% to $5.6 million in 2022, then decreased by 27.45% to $4.1 million in 2023, then fell by 27.34% to $3.0 million in 2024, then soared by 55.4% to $4.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $4.6 million in Q4 2025, $4.6 million in Q3 2025, and $2.3 million in Q2 2025.